Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid‐induced autism
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Rodents exposed prenatally to valproic acid (VPA) show autism‐related behavioral abnormalities. We recently found that prenatal VPA exposure causes a reduction of dopaminergic activity in the prefrontal cortex of male, but not female, mice. This suggests that reduced prefrontal dopaminergic activity is associated with behavioral abnormalities in VPA‐treated mice. In the present study, we examined whether the attention deficit/hyperactivity disorder drugs methylphenidate and atomoxetine (which increase dopamine release in the prefrontal cortex, but not striatum, in mice) could alleviate the behavioral abnormalities and changes in dendritic spine morphology induced by prenatal VPA exposure. We found that methylphenidate and atomoxetine increased prefrontal dopamine and noradrenaline release in VPA‐treated mice. Acute treatment with methylphenidate or atomoxetine did not alleviate the social interaction deficits or recognition memory impairment in VPA‐treated mice, while chronic treatment for 2 weeks did. Methylphenidate or atomoxetine for 2 weeks also improved the prenatal VPA‐induced decrease in dendritic spine density in the prefrontal cortex. The effects of these drugs on behaviors and dendritic spine morphology were antagonized by concomitant treatment with the dopamine‐D 1 receptor antagonist SCH39166 or the dopamine‐D 2 receptor antagonist raclopride, but not by the α 2‐adrenoceptor antagonist idazoxan. These findings suggest that chronic treatment with methylphenidate or atomoxetine improves abnormal behaviors and diminishes the reduction in spine density in VPA‐treated mice via a prefrontal dopaminergic system‐dependent mechanism. Autism Res 2016, 9: 926–939. © 2015 International Society for Autism Research, Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318179964f · Cited by 3,399 · cited 1×
“It is often accompanied by comorbid emotional and behavioral disturbances, including irritability, inattention, anxiety, and hyperactivity [Gotham, Brunwasser, & Lord, 2015; Mikita et al., 2015; Simonoff et al., 2008].”
BackgroundRisperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 2×
“Clinical studies show that the atypical antipsychotic drugs risperidone [McCracken et al., 2002; Shea et al., 2004] and aripiprazole [Marcus et al., 2009; Owen et al., 2009], and the ADHD drugs methylphenidate [Posey et al., 2007] and atomoxetine [Harfterkamp e al., 2012] improve abnormal behaviors…”
BackgroundDendritic spine pathology in neuropsychiatric disorders
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2741 · Cited by 1,523
Autism spectrum disorders: developmental disconnection syndromes
Geschwind, D. H., & Levitt, P. (2007) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2007.01.009 · Cited by 1,411
Behavioral Alterations in Rats Prenatally Exposed to Valproic Acid: Animal Model of Autism
Schneider, T., & Przewłocki, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300518 · Cited by 959 · cited 1×
“Rodents prenatally exposed to valproic acid (VPA) have been used as an animal model of ASD [Chomiak, Turner, & Hu, 2013; Kim et al., 2011; Roullet, Lai, & Foster, 2013; Schneider & Przewłocki, 2005; Wagner, Reuhl, Cheh, McRae, & Halladay, 2006].”
MethodAutistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2
Schmeisser, M. J., Ey, E., Wegener, S., Bockmann, J., Stempel, A. V., Kuebler, A., Janssen, A.-L., Udvardi, P. T., Shiban, E., Spilker, C., et al. (2012) · Nature · doi:10.1038/nature11015 · Cited by 638 · cited 1×
“Rodents prenatally exposed to valproic acid (VPA) have been used as an animal model of ASD [Chomiak, Turner, & Hu, 2013; Kim et al., 2011; Roullet, Lai, & Foster, 2013; Schneider & Przewłocki, 2005; Wagner, Reuhl, Cheh, McRae, & Halladay, 2006].”
MethodAripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 2×
“, 2004] and aripiprazole [Marcus et al., 2009; Owen et al., 2009], and the ADHD drugs methylphenidate [Posey et al.”
BackgroundPartial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593 · cited 2×
“…et al., 2011], Tsc1 mutant mice [Meikle et al., 2008], Ube3a mutant mice [Dindot, Antalffy, Bhattacharjee, & Beaudet, 2008], MeCP2 knockout mice [Tropea et al., 2009], CNTNAP2 knockout mice [Gdalyahu et al., 2015], and VPA-exposed rats [Bringas, Carvajal-Flores, L opez-Ram ırez, Atzori, &…”
Searching for ways out of the autism maze: genetic, epigenetic and environmental clues
Persico, A. M., & Bourgeron, T. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.05.010 · Cited by 575
Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3
Wang, X., McCoy, P. A., Rodriguiz, R. M., Pan, Y., Je, H. S., Roberts, A. C., Kim, C. J., Berrios, J., Colvin, J. S., Bousquet-Moore, D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr212 · Cited by 537
Cited by
An update on the comorbidity of ADHD and ASD: a focus on clinical management
Antshel, K. M., Zhang-James, Y., Wagner, K. E., Ledesma, A., & Faraone, S. V. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1146591 · Cited by 262
Methylphenidate for children and adolescents with autism spectrum disorder
Sturman, N., Deckx, L., & van Driel, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011144.pub2 · Cited by 135
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz041 · Cited by 92
Self-citationHara, Y., Ago, Y., Higuchi, M., Hasebe, S., Nakazawa, T., Hashimoto, H., Matsuda, T., & Takuma, K. (2017) · Hormones and Behavior · doi:10.1016/j.yhbeh.2017.09.013 · Cited by 61
Self-citationCircuits for social learning: a unified model and application to autism spectrum disorder
DeMayo, M. M., Young, L. J., Hickie, I. B., Song, Y. J. C., & Guastella, A. J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.034 · Cited by 52
Metadata
- Authors
- Hara, Y., Ago, Y., Taruta, A., Katashiba, K., Hasebe, S., Takano, E., Onaka, Y., Hashimoto, H., Matsuda, T., & Takuma, K.
- Venue
- Autism Research
- Publisher
- Wiley
- Published
- 2015-12-30
- Volume
- 9
- Issue
- 9
- Pages
- 926-939
- ISSN
- 1939-3792 (ISSN-L)
- 1939-3806
- OpenAlex
- W2219863134
- Cited by
- 59
- References
- 24
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid‐induced autism. https://app.cochat.ai/papers/10.1002/aur.1596
- The paper
- Hara, Y., Ago, Y., Taruta, A., Katashiba, K., Hasebe, S., Takano, E., Onaka, Y., Hashimoto, H., Matsuda, T., & Takuma, K. (2016). Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid‐induced autism. Autism Research. https://doi.org/10.1002/aur.1596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.